Spss v10 statistical software program

Comparisons of baseline characteristics between recipients who have received different doses of T cell depleting antibodies were examined by chi-square test and analysis of variance (ANOVA) for categorical and continuous variables respectively. For survival analyses, the follow up period was defined from the time of transplantation to the time of first cancer diagnoses after transplantation. Those who did not develop cancer were censored at the time of death or graft loss. The proportions free from incident cancers were calculated using the Kaplan-Meier Method. Results were expressed as hazard ratio (HR) or as odds ratio (OR) with 95% confidence intervals (CI). Covariates that were associated with cancer risk and had p-values of less than 0.2 in the unadjusted models were included in the adjusted models. All analyses were undertaken using SPSS V10 statistical software program (SPSS Inc., North Sydney, Australia) or SAS statistical software 9.4.

Data were expressed as number (proportion), mean±standard deviation (SD) and median and IQR where appropriate. Comparisons of baseline characteristics between cancer groups were made by chi-square test and analysis of variance (ANOVA) for categorical and continuous variables, respectively. The associations between incident cancer and outcomes were examined using the adjusted Cox proportional hazard regression analyses, with incident cancer considered as a time-varying covariate in all analyses. Covariates associated with each clinical outcome with p-values of <0.10 in the unadjusted analyses were included in the multivariable-adjusted analyses, although era, donor and recipient age were included because of their likely biological relationship with outcomes. Results were expressed as HR with 95%CI. Site-specific cancer Cox regression analyses were also conducted to assess the relationship between cancer types and death with a functioning graft (with time to event from cancer diagnosis). Sensitivity analysis excluding incident cancers that had occurred within the first 2 years after transplant was undertaken. All analyses were undertaken using SPSS V10 statistical software program (SPSS Inc., North Sydney, Australia) and STATA (version 11 STATACorp LP, College Station, TX).